Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and ac
Two investment funds have decided to contest Taisho Pharma’s recently announced management buyout plan in court, after failing to reach an agreement on the price.
Ligand Pharmaceuticals has made its second major acquisition in 2024, agreeing a $100 million deal to buy Austria’s Apeiron Biologics and a royalty stream for brain cancer drug Qarziba.
After languishing in the doldrums for a few quarters, there are signs that the winds of investment are starting to blow again in the US digital health sector, according to market watcher Ro
Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057.